Accepted Manuscript

Antifungal drug ciclopirox olamine reduces HSV-1 replication and disease in mice

Kaelin M. Bernier, Lynda A. Morrison

PII: S0166-3542(18)30316-4

DOI: 10.1016/j.antiviral.2018.06.010

Reference: AVR 4314

To appear in: Antiviral Research

Received Date: 17 May 2018

Accepted Date: 12 June 2018

Please cite this article as: Bernier, K.M., Morrison, L.A., Antifungal drug ciclopirox olamine reduces HSV-1 replication and disease in mice, *Antiviral Research* (2018), doi: 10.1016/j.antiviral.2018.06.010.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

Antifungal drug ciclopirox olamine reduces HSV-1 replication and disease in mice

Kaelin M. Bernier^{a1} and Lynda A. Morrison^a

^aDepartment of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, 1100 S. Grand Blvd., St. Louis, Missouri, 63104 U.S.A.

¹Current address: Midwestern University, 19555 N. 59th Ave., Glendale, Arizona 85308 U.S.A. kbernier83@midwestern.edu

Corresponding author:

Lynda Morrison

Phone: 314-977-8874

e-mail: lynda.morrison@health.slu.edu

Short title: Ciclopirox olamine reduces HSV-1 replication and disease in mice

Keywords: herpes simplex virus; ciclopirox; corneal; replication; antiviral

Declaration of interests: LM is an inventor on a patent application covering use of ciclopirox and ciclopirox olamine for HSV-1 and HSV-2, and is a scientific advisor to Casterbridge Pharmaceuticals, Inc.

1

Download English Version:

https://daneshyari.com/en/article/8523107

Download Persian Version:

https://daneshyari.com/article/8523107

Daneshyari.com